Post on 05-Apr-2018
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
1/12
John F. Hernandez, MSN, CRNA, Janet A. Secrest,PhD, RN, Linda Hill, CRNA, DNSc, S. Jack
McClarty, MD
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
2/12
Introduction.
Background.
Diagnosis and managment of MH.
Genetic Basis.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
3/12
Malignant Hyperthermia (MH) is a potentially fataldisorder triggered by certain types of generalanesthesia.
Genetic basis recognized in the early 1990.
Diagnosis and genetic bases.
The mortality rate are app. 10% compared with 70
80% originally. This reduction is the result ofincreased awareness of the condition by anaesthetistsand improved standards of perioperative monitoring,together with the specific drug treatment, dantrolene.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
4/12
The first case was reported in1960, a fracture repair withgeneral anesthesia.
The familial history ofanesthesia-related deaths withthe use of ether.
A cooling bath with bloodtransfusion. 90 minutes to fullrecovery.
13 months later the patientsreturns for a calculus extractionunder spinal Anesthesia without
adversity. 10 relatives had similar clinical
experiences and presented withfever up to 43C, convulsions,and ultimately death.
The anesthesiologist concludedthat a genetic link existed amongthe family members.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
5/12
Malignant
Hyperthermia (MH)
Genetic basis, triggered byAnesthetics
Hypercarbia.
Increased metabolic state, lossof calcium homeostasis.
Hyperpyrexia.
Genetic linkagesitill not completely
understood.
RyR1
High level ofDioxide carbon High fever
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
6/12
MH is typically associated with malfunctions in the, MH is especially a risk for patients with in the
receptor and who take hydrocarbon .
MH is the in muscles with excessiveoxygen consumption.
In MH,receptors are defective and
they release excessive Ca++which needs to be reabsorbed,this requires a lot of ATP.Excess mitochondrial oxidativephosphorylation cycles occurto generate this, leading toheat generation(hyperthermia).
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
7/12
Unexplained increase in bothheart rate and carbon dioxide
Clinical features :
Hypercarbia
Tachycardia
Hyperthermia
Matabolic acidosis
Cyanosis
Spasm, rigidity, contracture Renal failure
Intravascular coagulopathy
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
8/12
None of the features listed previously are unique, the diagnosisof malignant hyperthermia and the diagnosis can be difficult.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
9/12
Early DNA family studiesshowed linkage between theRyR1 gene on chromosome19q12-13.2 and MH.
Only 60% of European familieswith MH have been shown tohave linkeage to RyR1.
RyR1 is a large gene and over
100 mutations have been nowindentified, but only 22 haveevidence of functional activity.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
10/12
Attempts to identify all causal mutations haveresulted in the discovery of new RyR1mutation types
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
11/12
Other chromosomal cause were suspected inpatients who lack de Ryanodine mutation.
Althoug MHS1 has been the only geneticcause of direct MH, The additional presenceof MHS3, MHS4, MHS5 mutations may interactin phenotype expression in some individuals.
7/31/2019 [4]Scientific Advances in Malignant Hyperthermia
12/12